Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/50557
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record
CARDIOVASCULAR AUTONOMIC NEUROPATHY IN DIABETES: PATHOPHYSIOLOGY, CLINICAL ASSESSMENT AND IMPLICATIONS
Cardiovascular autonomic neuropathy
Diabetes mellitus
Heart rate variability
Parasympathetic autonomic nervous system
Sympathetic autonomic nervous system
Affilliation
Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Cardiologia. Departamento de Educação e Pesquisa. Rio de Janeiro, RJ, Brasil.
Abstract
Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition.
Keywords
Cardiac autonomic neuropathyCardiovascular autonomic neuropathy
Diabetes mellitus
Heart rate variability
Parasympathetic autonomic nervous system
Sympathetic autonomic nervous system
Share